Phantom Pharma (PHAT) is in the Barchart Top 10 Gastrointestinal drug developer Losing money according the Aug 2 report but still has over $200 million cash plus another $100 million equity line
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.